Hybio Pharmaceutical Co., Ltd.: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Hybio Pharmaceutical Co., Ltd.?
Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Hybio Pharmaceutical Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Feb 9, 2026 to Jun 30, 2026. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Shenzhen
- FEI numbers on the lines
- 3026377169
- Refused lines
- 2
- Lines with an Import Alert 66-80 API or powder code
- 1
- Drugs named in the product codes
- Semaglutide, Tirzepatide
- Refusal dates
- Feb 9, 2026 to Jun 30, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hybio Pharmaceutical Co., Ltd. is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Jun 30, 2026 | China | 61PBY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 8NP-0146038-9/10002/1 |
| Feb 9, 2026 | China | 61PDR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 799-2538313-8/10003/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 2 |
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 1 |
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 1 |
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 46 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Hybio Pharmaceutical Co., Ltd.”, “Hybio Pharmaceutical Co. Ltd” and “Hybio Pharmaceutical Co., Ltd”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (26); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (20).
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Jun 16, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 6, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 13, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 12, 2025 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 4, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Feb 5, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 7, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0018 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 28, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 17, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 18, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 22, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 22, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co. Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Mar 28, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0029 | Hybio Pharmaceutical Co. Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 16, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 1, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 14403-0027 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 13, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0028 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 23, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 14403-0028 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 23, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.
2 lines from FDA files read Nov 15, 2026.